The University of Michigan has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked estrogen receptor (ER) targeting moiety reported to be useful for the treatment of breast cancer.
Cleara Biotech BV has closed a $2.5 million seed financing round, the proceeds of which will be used to progress its compounds toward clinical development and build the company's developmental pipeline.
Abpro Corp. and Celltrion Healthcare Inc. entered a global partnership valued at up to $1.75 billion involving ABP-102, a bispecific antibody targeting HER2-positive cancers, a move Abpro CEO Ian Chan said would help “accelerate this type of therapy for patients in need.”
Abpro Corp. has entered into a strategic partnership with Celltrion Holdings Co. Ltd. for ABP-102, a bispecific antibody therapy for patients with HER2+ cancer, including breast, gastric and pancreatic cancers.
Abpro Corp. and Celltrion Healthcare Inc. entered a global partnership valued at up to $1.75 billion involving ABP-102, a bispecific antibody targeting HER2-positive cancers, a move Abpro CEO Ian Chan said would help “accelerate this type of therapy for patients in need.” With ABP-102 in preclinical development, Abpro decided to start looking for a partner. HER2 is “one of the biggest targets in biotech, mostly relevant for breast, colorectal and gastric cancers,” Chan told BioWorld. “Celltrion happened to have a lot of experience in the space.”
Seecure Taiwan Co. Ltd. has disclosed compounds reported to be useful for the treatment or diagnosis of cancer, autoimmune diseases and atherosclerosis.
Challenges scheduling time for a mammogram, frustration waiting for the exam itself and pain from the test have caused any number of women to cry. Namida Lab Inc. may take the inconvenience and anxiety out of breast health assessment with its Auria test, but the tears will stay. Like a growing number of assays, the test uses tear-based analytics to determine cancer risk.
University of Chicago has described estrogen receptor (ER)-α antagonists reported to be useful for the treatment of cancer, fibroids, uterine (myoma), hormone replacement therapy, menopause, obesity, osteoporosis and atrophic vulvovaginitis.
